“over the next couple of weeks, we expect, our IND to be, opened by the FDA. And then our phase two study will begin in earnest, next quarter, in the third quarter”
→ Read the source episode
FDA clears GAIN's IND application and Phase 2 study initiates in Q3 2026 (by September 30, 2026)
Jean Mack predicts Phase 2 will enroll patients across Australia, potentially Europe, and the United States
Deborah Research will identify and move the most promising read-through molecule candidates into first-in-human clinical studies.
Deborah Research is supporting development of a self-cooling sole for sneakers to address blister problems in EB patients.
Lu Gao predicts Therona will file INDs in parallel in the US and China in Q4 2026
Andy Parker predicts StepPharma will raise additional funding within next six months (by January 2027).
Andy Parker predicts StepPharma will move lymphoma trial into safety expansion cohort and make phase two decisions by end of 2026.
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.